-
1
-
-
12944291461
-
Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation
-
DOI 10.1002/ajmg.a.30388
-
Carballo M, Roig I, Aguilar F, et al. Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation. Am J Med Genet A. 2005;132(4):361-364. (Pubitemid 40175584)
-
(2005)
American Journal of Medical Genetics
, vol.132 A
, Issue.4
, pp. 361-364
-
-
Carballo, M.1
Roig, I.2
Aguilar, F.3
Pol, M.A.4
Gamundi, M.J.5
Hernan, I.6
Martinez-Gimeno, M.7
-
3
-
-
12144286747
-
Pleomorphic Characteristics of a Germ-Line KIT Mutation in a Large Kindred with Gastrointestinal Stromal Tumors, Hyperpigmentation, and Dysphagia
-
DOI 10.1158/1078-0432.CCR-03-0110
-
Robson ME, Glogowski E, Sommer G, et al. Pleomorphic characteristics of a germline KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res. 2004;10(4):1250-1254. (Pubitemid 38365214)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.4
, pp. 1250-1254
-
-
Robson, M.E.1
Glogowski, E.2
Sommer, G.3
Antonescu, C.R.4
Nafa, K.5
Maki, R.G.6
Ellis, N.7
Besmer, P.8
Brennan, M.9
Offit, K.10
-
4
-
-
72749115279
-
-
Life Raft Group Web site. Accessed August 8, 2008.
-
Familial GIST. Life Raft Group Web site. http://www.liferaftgroup.org/ gist-familial.html. Accessed August 8, 2008.
-
-
-
-
5
-
-
2342582667
-
C-kit mutation in generalized lentigines associated with gastrointestinal stromal tumor
-
DOI 10.1159/000077302
-
Shibusawa Y, Tamura A, Mochiki E, Kamisaka K, Kimura H, Ishikawa O. C-kit mutation in generalized lentigines associated with gastrointestinal stromal tumor. Dermatology. 2004;208(3):217-220. (Pubitemid 38594534)
-
(2004)
Dermatology
, vol.208
, Issue.3
, pp. 217-220
-
-
Shibusawa, Y.1
Tamura, A.2
Mochiki, E.3
Kamisaka, K.4
Kimura, H.5
Ishikawa, O.6
-
6
-
-
33749459756
-
Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis
-
Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130(10):1466-1478. (Pubitemid 44520713)
-
(2006)
Archives of Pathology and Laboratory Medicine
, vol.130
, Issue.10
, pp. 1466-1478
-
-
Miettinen, M.1
Lasota, J.2
-
7
-
-
0344412948
-
Imatinib Mesylate Causes Hypopigmentation in the Skin
-
DOI 10.1002/cncr.11812
-
Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003;98(11):2483-2487. (Pubitemid 37466664)
-
(2003)
Cancer
, vol.98
, Issue.11
, pp. 2483-2487
-
-
Tsao, A.S.1
Kantarjian, H.2
Cortes, J.3
O'Brien, S.4
Talpaz, M.5
-
8
-
-
0028967971
-
Expression of the c-kit receptor in hypomelanosis: A comparative study between piebaldism, nevus depigmentosus and vitiligo
-
Dippel E, Haas N, Grabbe J, Schadendorf D, Hamann K, Czarnetzki BM. Expression of the c-kit receptor in hypomelanosis: a comparative study between piebaldism, nevus depigmentosus and vitiligo. Br J Dermatol. 1995;132(2):182-189.
-
(1995)
Br J Dermatol
, vol.132
, Issue.2
, pp. 182-189
-
-
Dippel, E.1
Haas, N.2
Grabbe, J.3
Schadendorf, D.4
Hamann, K.5
Czarnetzki, B.M.6
-
9
-
-
24344482523
-
Imatinib mesilate (Glivec): A systemic depigmenting agent for extensive vitiligo? [17]
-
DOI 10.1111/j.1365-2133.2005.06813.x
-
Legros L, Cassuto J-P, Ortonne J-P. Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo? Br J Dermatol. 2005;153(3):691-692. (Pubitemid 41248249)
-
(2005)
British Journal of Dermatology
, vol.153
, Issue.3
, pp. 691-692
-
-
Legros, L.1
Cassuto, J.-P.2
Ortonne, J.-P.3
-
10
-
-
72749088767
-
-
East Hanover, NJ Novartis Pharmaceuticals Corp
-
Gleevec [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corp; 2006.
-
(2006)
Gleevec [Package Insert]
-
-
-
11
-
-
33745879177
-
Imatinib mesilate inhibits melanogenesis in vitro
-
letter
-
Cario-André M, Ardilouze L, Pain C, Gauthier Y, Mahon FX, Taieb A. Imatinib mesilate inhibits melanogenesis in vitro [letter]. Br J Dermatol. 2006;155(2):493-494.
-
(2006)
Br J Dermatol
, vol.155
, Issue.2
, pp. 493-494
-
-
Cario-André, M.1
Ardilouze, L.2
Pain, C.3
Gauthier, Y.4
Mahon, F.X.5
Taieb, A.6
-
12
-
-
1542316943
-
Hypopigmentation from imatinib mesylate (Gleevec)
-
Grossman WJ, Wilson DB. Hypopigmentation from imatinib mesylate (Gleevec). J Pediatr Hematol Oncol. 2004;26(3):214.
-
(2004)
J Pediatr Hematol Oncol
, vol.26
, Issue.3
, pp. 214
-
-
Grossman, W.J.1
Wilson, D.B.2
-
15
-
-
48749104326
-
Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST
-
Accessed August 5, 2008
-
Alexandrescu D, Dasanu C, Farzanmehr H, Kauffman L. Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J. 2008;14(7):7. http://dermatology.cdlib.org/147/case-report/ gleevec-hyperpigmentation/doru.html. Accessed August 5, 2008.
-
(2008)
Dermatol Online J
, vol.14
, Issue.7
, pp. 7
-
-
Alexandrescu, D.1
Dasanu, C.2
Farzanmehr, H.3
Kauffman, L.4
-
16
-
-
57649166233
-
Imatinib-associated hyperpigmentation, a side effect that should be recognized
-
Mcpherson T, Sherman V, Turner R. Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol. 2009;23(1):82-83.
-
(2009)
J Eur Acad Dermatol Venereol
, vol.23
, Issue.1
, pp. 82-83
-
-
Mcpherson, T.1
Sherman, V.2
Turner, R.3
-
17
-
-
23744512047
-
An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients
-
DOI 10.1097/00008390-200508000-00008
-
Alexis JB, Martinez AE, Lutzky J. An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res. 2005;15(4):283-285. (Pubitemid 41127464)
-
(2005)
Melanoma Research
, vol.15
, Issue.4
, pp. 283-285
-
-
Alexis, J.B.1
Martinez, A.E.2
Lutzky, J.3
-
18
-
-
0642368571
-
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
-
DOI 10.1200/JCO.2003.04.190
-
Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342-4349. (Pubitemid 46621810)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.23
, pp. 4342-4349
-
-
Heinrich, M.C.1
Corless, C.L.2
Demetri, G.D.3
Blanke, C.D.4
Von Mehren, M.5
Joensuu, H.6
McGreevey, L.S.7
Chen, C.-J.8
Van Den Abbeele, A.D.9
Druker, B.J.10
Kiese, B.11
Eisenberg, B.12
Roberts, P.J.13
Singer, S.14
Fletcher, C.D.M.15
Silberman, S.16
Dimitrijevic, S.17
Fletcher, J.A.18
|